The Department of Health and Human Services today announced a $226 million contract to expand the nation’s capacity to quickly produce vaccine for a flu pandemic. HHS expects the six-year agreement with Sanofi Pasteur to increase the company’s capacity to use recombinant vaccine technology, which is faster than traditional egg-based technology, to produce a pandemic vaccine in the United States to nearly 100 million doses. Sanofi is the only company with a seasonal recombinant flu vaccine licensed in the U.S. “Keeping vaccine manufacturing in the United States is essential to protect Americans from pandemic influenza and to save lives,” said BARDA Director Rick Bright. “Better, faster vaccine technologies, produced in the U.S. will improve access, protect more people and, ultimately, strengthen our nation’s health security.” In September, President Trump created an interagency task force to develop and implement a five-year plan to improve flu vaccines and produce them faster.

 

Related News Articles

Headline
To continue emphasizing the message of protecting against both the flu and COVID-19, AHA’s Wear A Mask and United Against the Flu campaigns today released new…
Headline
This podcast, in support of AHA’s national strategic alliance with the National Urban League, is bringing attention to health inequities in Black and…
Headline
The Food and Drug Administration Friday authorized the first prescription diagnostic test for both COVID-19 and influenza A and B that allows patients to…
Headline
The Food and Drug Administration yesterday approved using the antiviral treatment Xofluza (baloxavir marboxil) to prevent flu in patients age 12 or older who…
Headline
Adam Myers, M.D., population health chief at Cleveland Clinic, talks with Nancy Foster, AHA vice president for quality and patient safety, about preventing flu…
Headline
The Food and Drug Administration yesterday released an updated template for developers requesting emergency use authorization for antigen tests for…